<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Res Protoc</journal-id><journal-id journal-id-type="publisher-id">ResProt</journal-id><journal-id journal-id-type="index">5</journal-id><journal-title>JMIR Research Protocols</journal-title><abbrev-journal-title>JMIR Res Protoc</abbrev-journal-title><issn pub-type="epub">1929-0748</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v15i1e80214</article-id><article-id pub-id-type="doi">10.2196/80214</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Developing and Evaluating a WeChat-Based Applet Fluid Intake Reminder on Enhancing Fluid Adherence in Postoperative Patients With Urinary Calculi: Protocol for a Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Xue</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names>Tongyao</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names>Qian</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><institution>School of Nursing, Li Ka Shing Faculty of Medicine, University of Hong Kong</institution><addr-line>Room 532, Academic Building at No 3, Sassoon Road, Pokfulam</addr-line><addr-line>Hong Kong</addr-line><country>China (Hong Kong)</country></aff><aff id="aff2"><institution>Department of Urology, Shenzhen Qianhai Shekou Free Trade Zone Hospital</institution><addr-line>Shenzhen</addr-line><country>China</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Schwartz</surname><given-names>Amy</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Wang</surname><given-names>Siqian</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Tongyao Wang, PhD, School of Nursing, Li Ka Shing Faculty of Medicine, University of Hong Kong, Room 532, Academic Building at No 3, Sassoon Road, Pokfulam, Hong Kong, China (Hong Kong), 852 39102790; <email>tongyao1@hku.hk</email></corresp></author-notes><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2026</year></pub-date><volume>15</volume><elocation-id>e80214</elocation-id><history><date date-type="received"><day>06</day><month>07</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>01</month><year>2026</year></date></history><copyright-statement>&#x00A9; Xue Zhou, Tongyao Wang, Qian Chen. Originally published in JMIR Research Protocols (<ext-link ext-link-type="uri" xlink:href="https://www.researchprotocols.org">https://www.researchprotocols.org</ext-link>), 19.2.2026. </copyright-statement><copyright-year>2026</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://www.researchprotocols.org">https://www.researchprotocols.org</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://www.researchprotocols.org/2026/1/e80214"/><abstract><sec><title>Background</title><p>Urinary calculi (UC), affecting 1%&#x2010;13% globally, pose a significant health burden due to high recurrence rates (up to 50% within 10 years) and substantial health care costs. Adequate fluid intake is a cornerstone of prevention; yet, its adherence remains poor due to forgetfulness, lifestyle barriers, and limited patient education. Existing mobile health interventions for UC prevention often lack medical oversight and clinical validation. WeChat-based digital therapeutic intervention may have a positive effect on fluid adherence in this patient group.</p></sec><sec><title>Objective</title><p>Our objective is to develop a WeChat applet to improve hydration behavior and reduce stone recurrence among postoperative patients with UC.</p></sec><sec sec-type="methods"><title>Methods</title><p>This is an open-label, 2-arm, parallel-group randomized controlled trial. We will recruit 148 participants from China&#x2019;s tertiary hospital and randomly allocate them in a ratio of 1:1 to the intervention or control group. The intervention group received standard postoperative care supplemented by the WeChat-Based Applet Fluid Intake Reminder (WAFIR), which delivers personalized fluid intake reminders, urine color monitoring, 24-hour fluid intake and urine output tracking, and evidence-based educational content on hydration and urolithiasis management. The control group receives standard care of general discharge instructions from nurses. The primary outcome is the fluid adherence, measured by 24-hour fluid intake and urine volume; secondary outcome measures are the Wisconsin Stone Quality of Life Questionnaire, Patient Health Questionnaire-9, Electronic Health Literacy Scale, physical activity (International Physical Activity Questionnaire&#x2014;Short Form), and recurrence rate of UC. Outcomes are measured before intervention (T0) and after a 1-month (T1) and 3-month (T2) follow-up period. Intention-to-treat analysis, 2-tailed <italic>t</italic> tests, and repeated measures ANOVA will be used to compare outcomes; statistical significance is set at a <italic>P</italic>&#x003C;.05 significance threshold. The study was approved by the ethics review board in December 2024.</p></sec><sec sec-type="results"><title>Results</title><p>The development of WAFIR, conducted in collaboration with stakeholders, was finalized in February 2025. Recruitment commenced on March 1, 2025; data collection was completed in September 2025, and data analysis was analyzed in December 2025. Dissemination of findings is planned through conferences and publications in 2026.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This research evaluates the effectiveness of a nurse-led, evidence-based digital therapeutic intervention, WAFIR, in overcoming fluid adherence barriers among postoperative patients following urolithiasis surgery, aiming to increase daily fluid intake and urine output, reduce recurrence rates, enhance quality of life, and generate empirical evidence for its application in urology care, thereby optimizing postoperative management within clinical settings.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov NCT06990672; https://clinicaltrials.gov/study/NCT06990672</p></sec><sec sec-type="registered-report"><title>International Registered Report Identifier (IRRID)</title><p>DERR1-10.2196/80214</p></sec></abstract><kwd-group><kwd>fluid adherence</kwd><kwd>urinary calculi</kwd><kwd>digital therapeutic</kwd><kwd>WeChat applet</kwd><kwd>fluid reminder</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Urolithiasis, or urinary calculi (UC), is emerging as a significant global health crisis, affecting individuals of all ages and genders. The prevalence of UC has been increasing worldwide over the past decades [<xref ref-type="bibr" rid="ref1">1</xref>]. Estimated incidence rates are 7%&#x2010;13% in North America, 5%&#x2010;9% in Europe, and 1%&#x2010;5% in Asia [<xref ref-type="bibr" rid="ref2">2</xref>]. In low-income countries, up to 25% of the population can be affected, often with fatal outcomes due to inadequate urological care [<xref ref-type="bibr" rid="ref3">3</xref>]. In China, the prevalence of nephrolithiasis is around 5.8%, exceeding 10% in the southern region [<xref ref-type="bibr" rid="ref4">4</xref>]. Meanwhile, the high recurrence rate of UC poses a significant challenge, with approximately 10%, 30%, and 50% of individuals experiencing recurrence at 1 year, 5 years, and 10 years, respectively [<xref ref-type="bibr" rid="ref5">5</xref>-<xref ref-type="bibr" rid="ref7">7</xref>]. The financial burden of UC is substantial, with yearly medical expenses estimated at 10 billion dollars in the United States and US $695.51 million in Europe [<xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref>]. Predictive models indicate that the high prevalence and recurrence rate will lead to a 25% increase in health care costs over the next 50 years [<xref ref-type="bibr" rid="ref10">10</xref>]. This makes UC one of the most expensive urological diseases, highlighting the urgent need for better understanding and management of this condition.</p><p>The occurrence of UC is influenced by a variety of environmental, climatic, and dietary factors. Environmental and climatic conditions, particularly in hot climates, can contribute significantly to water loss and water quality issues. High temperatures often lead to increased perspiration, which in turn reduces overall water levels in the body. This dehydration can concentrate the urine, increasing the likelihood of stone formation. Additionally, water quality, specifically the levels of sodium and other minerals, plays a crucial role in this process [<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref>]. Dietary habits are another critical factor in the development of urinary stones. Insufficient water intake is one of the primary dietary risk factors, as it leads to more concentrated urine, which facilitates the crystallization process. Poor dietary habits, such as the prolonged consumption of oxalate-rich foods&#x2014;like spinach, nuts, and chocolates&#x2014;significantly elevate the propensity for developing calcium oxalate stones [<xref ref-type="bibr" rid="ref13">13</xref>]. High-sugar and high-fat diets further exacerbate this risk by influencing urinary elimination processes, making the urine more conducive to stone formation [<xref ref-type="bibr" rid="ref14">14</xref>]. These risk factors highlight the important role of nurses in implementing targeted hydration protocols and dietary interventions to mitigate stone recurrence.</p><p>The European Association of Urology and the American Urological Association both strongly emphasize the importance of increasing fluid intake to prevent urinary stone formation. Research indicates that increasing fluid consumption stands out as a simple and economically feasible way to lower the risk of stone formation [<xref ref-type="bibr" rid="ref15">15</xref>]. Then, McCauley et al [<xref ref-type="bibr" rid="ref16">16</xref>] discovered that patients tend to be more open to increasing fluid intake than adopting other dietary or pharmaceutical therapies. Yet, Khambti et al [<xref ref-type="bibr" rid="ref17">17</xref>] identified a challenge, noting that only about half of patients with urinary stones adhere to hydration recommendations, as determined through 24-hour urine output tests. Building on this, further research elucidated the underlying causes: at first, patients might not know or remember to drink enough; then, some dislike the taste of water or do not feel thirsty; and finally, the need for frequent voiding or workplace factors gets in the way [<xref ref-type="bibr" rid="ref16">16</xref>]. Other research backs this up, showing that forgetfulness or not realizing their need for hydration plays a big role in poor fluid habits [<xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref>]. Therefore, enhancing adherence to fluid intake recommendations offers substantial benefits, including reduced health care expenditure through lower incidence of urinary stones and associated costs, improved public health outcomes, and an elevated quality of life (QoL) by decreasing the frequency and severity of symptoms.</p><p>Digital therapeutic interventions (DTx) deliver evidence-based, software-driven solutions via mobile apps, wearables, and web platforms to manage conditions. Unlike wellness tools, DTx is clinically validated, often regulated, and designed for measurable health outcomes [<xref ref-type="bibr" rid="ref20">20</xref>]. By 2026, the global mobile app market was expansive, with approximately 4 million apps available on the Apple App Store and Google Play, reflecting the vast potential of digital health tools [<xref ref-type="bibr" rid="ref21">21</xref>]. However, conventional mobile apps face significant barriers to widespread adoption, such as complex development processes, protracted timelines, and substantial financial investment, which often limit their scalability and accessibility in clinical settings. In contrast, WeChat applets, which require no installation and are integrated into China&#x2019;s predominant social media platform, facilitate seamless, on-demand access, effectively addressing technical barriers and offering distinct advantages by enhancing user convenience and minimizing operational challenges. With over 1.4 billion monthly active users, WeChat has a vast reach and engagement, making it a widely used communication tool in China. Using WeChat&#x2019;s existing infrastructure, the applets simplify the process by reducing the need for extensive coding and platform-specific adaptation and allow individuals to access them instantly. The significance of WeChat in health care has been amplified by its rapid adoption during the COVID-19 pandemic, which catalyzed its integration into various medical contexts, from telemedicine to patient education, markedly improving care quality [<xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref>]. Notably, the feasibility of using WeChat to enhance adherence to prevention strategies has been demonstrated among multiple chronic diseases [<xref ref-type="bibr" rid="ref24">24</xref>]. WeChat-based DTx overcomes conventional mobile app barriers and drives health care innovation by enhancing patient adherence and care quality across diverse medical contexts, including chronic disease management and preventive strategies.</p><p>Previous studies have highlighted the limitations in the current landscape of DTx for fluid management and urinary stone prevention. Stevens et al [<xref ref-type="bibr" rid="ref25">25</xref>] noted that many apps lack the support of medical professionals, leading to the dissemination of potentially false information and inaccuracies that could negatively impact patient health. This underscores the importance of involving medical professionals in the development and content review of these apps to ensure their reliability and clinical validity. The advent of digital technologies, such as wearable devices and intelligent water bottles, has introduced new methods for monitoring water intake and preventing urinary stones. However, the effectiveness of these devices is highly dependent on the practicality of their use. For instance, patients may not always have access to smart bottles in all settings, which can lead to incomplete fluid intake records. Karag&#x00F6;z and Sar&#x0131;ca [<xref ref-type="bibr" rid="ref26">26</xref>] further pointed out that the high cost and inconvenience associated with these devices may deter long-term patient compliance, highlighting the need for more cost-effective and user-friendly solutions for fluid intake notification. A review of the literature reveals that most published studies are small-scale, single-arm pilot interventions lacking robust controlled trials designed to evaluate long-term effectiveness and adherence. Moreover, Philip-McKenzie et al [<xref ref-type="bibr" rid="ref27">27</xref>] analyzed 51 apps from the Apple and Google Play Store and found that none of the apps measured urine volume and color, and only 1 provided medical advice or educational content regarding the consequences of poor hydration. This reveals a substantial gap in the provision of comprehensive medical advice and education within these apps to improve patients&#x2019; recognition of disease severity. Furthermore, Winoker et al [<xref ref-type="bibr" rid="ref28">28</xref>] highlighted the scarcity of evidence supporting the benefits of mobile health (mHealth) interventions in urological care and emphasized the need for more rigorous research to validate the effectiveness of these technologies. Karag&#x00F6;z and Sar&#x0131;ca [<xref ref-type="bibr" rid="ref26">26</xref>] also recommended that future research should focus on the practicality, security, efficacy, and overall benefits of these apps in preventing stone recurrence.</p><p>This study aims to investigate the efficacy of the WeChat-Based Applet Fluid Intake Reminder (WAFIR) in improving fluid intake among postoperative patients with UC compared to standard care, with the ultimate goal of reducing stone recurrence and enhancing patient well-being. The specific objectives are to quantify changes in daily fluid intake and urine output, evaluate its effect on the QoL, and determine its influence on readmission rates, recurrence rates, and eHealth literacy over the follow-up period. We hypothesize that patients receiving WAFIR exhibit statistically significant differences in 24-hour urine output (mL), fluid intake (mL/24 hours), QoL (Wisconsin Stone Quality of Life Questionnaire [WISQOL] score), eHealth literacy (Electronic Health Literacy Scale [eHEALS] score), or urinary stone recurrence rates (3-month follow-up) compared to those receiving usual care.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Research Design</title><p>We will conduct a 3-month, 2-arm randomized controlled trial (RCT) involving participants assigned to either a WAFIR intervention group or standard care group. Participants will be enrolled in batches, using block randomization with blocks of 10, and allocated in a 1:1 ratio, with a total sample size of 148 participants determined. An independent researcher (QC) will generate the randomization list using the sealed envelope method. A detailed research technology roadmap is displayed in <xref ref-type="fig" rid="figure1">Figure 1</xref>. Key aspects of the study design can be found in <xref ref-type="fig" rid="figure2">Figure 2</xref>.</p><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>RCT CONSORT flowchart. CONSORT: Consolidated Standards of Reporting Trials; eHEALS: Electronic Health Literacy Scale; IPAQ-SF: International Physical Activity Questionnaire&#x2014;Short Form; PHQ-9: Patient Health Questionnaire-9; RCT: randomized controlled trial; WISQOL: Wisconsin Stone Quality of Life Questionnaire.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="resprot_v15i1e80214_fig01.png"/></fig><fig position="float" id="figure2"><label>Figure 2.</label><caption><p>Study design table. MARS: Mobile App Rating Scale; WAFIR: WeChat-Based Applet Fluid Intake Reminder.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="resprot_v15i1e80214_fig02.png"/></fig></sec><sec id="s2-2"><title>Characteristics of Participants</title><p>The study is open to individuals aged 18 years or older, diagnosed with UC and admitted to Shekou Free Trade Zone Hospital (a tertiary general hospital) for urinary stone surgery, to participate. Eligible patients will be enrolled prior to discharge, either by a nephrologist or a urologist (<xref ref-type="other" rid="box1">Textbox 1</xref>).</p><boxed-text id="box1"><title> Inclusion, exclusion, and withdrawal criteria for participants&#x2019; recruitment.</title><p><bold>Inclusion criteria</bold></p><list list-type="bullet"><list-item><p>With a history of urinary calculi and having received urolithiasis surgery before.</p></list-item><list-item><p>24-hour fluid intake &#x003C;2500 mL.</p></list-item><list-item><p>Age &#x2265;18 years.</p></list-item><list-item><p>Able to use WeChat daily.</p></list-item><list-item><p>Able to read and write informed consent.</p></list-item></list><p><bold>Exclusion criteria</bold></p><list list-type="bullet"><list-item><p>Participants with obstructive uropathy, chronic urosepsis, renal failure, and renal tubular acidosis.</p></list-item><list-item><p>Participants with congestive heart failure, psychiatric conditions, pregnancy, and primary hyperparathyroidism.</p></list-item><list-item><p>Participants experienced complicated urolithiasis surgery (surgical procedures for urolithiasis that involve complex interventions, often requiring multiple operations during the follow-up period due to factors such as large stone burden, anatomical abnormalities, or postoperative complications, eg, percutaneous nephrolithotomy with residual stones or ureteroscopy requiring reintervention).</p></list-item><list-item><p>History of recurrent urinary tract infection (&#x003E;3 per year).</p></list-item><list-item><p>Medication use increases stone risk.</p></list-item><list-item><p>Participants with physical disabilities.</p></list-item></list><p><bold>Withdrawal criteria</bold></p><list list-type="bullet"><list-item><p>Participants will be deemed to have withdrawn from the study upon the voluntary withdrawal of their consent or if they fail to return a postintervention assessment within 30 days after the end of the intervention phase. All instances of withdrawal and the discontinuation of any participant&#x2019;s involvement in the trial are meticulously documented.</p></list-item></list></boxed-text></sec><sec id="s2-3"><title>Intervention</title><sec id="s2-3-1"><title>Standard Care</title><p>Participants will receive standard dietary and regular recommendations, including an education profile and counseling to achieve a water intake and urine output &#x2265;2500 mL, along with verbal health education counseling regarding urological calculi prevention during hospitalization and guidance on adequate hydration at discharge. A fixed-capacity water bottle will be provided. Phone calls will be given at each follow-up phase to reinforce the educational content and collect primary and secondary data through questionnaires.</p></sec><sec id="s2-3-2"><title>WAFIR Intervention</title><p>Participants will receive the standard dietary counseling and an educational handout. The WAFIR will be introduced to the intervention group to enhance adherence to fluid intake and facilitate self-monitoring for the prevention of UC. The WAFIR will include features such as fluid intake reminders, fluid and urine value recording, urine color tracking, and health education, as well as an interactive group for communication among postoperative patients with urinary stones. The WAFIR will deliver personalized daily notifications to remind participants of increasing fluid intake exceeding 2500 mL. Additional educational content highlighting the benefits of adherence will be provided to the experimental group through the applet as well. Phone calls will be given at each follow-up phase to collect primary and secondary data via the questionnaires.</p><p>To address the limitations observed in existing mobile apps, we are developing an innovative WAFIR aimed at improving participants&#x2019; adherence to fluid intake and reducing the recurrence of UC. This intervention will incorporate multiple functionalities to enhance participants&#x2019; awareness and control over their fluid consumption. The WAFIR will consist of 4 main pages:</p><list list-type="bullet"><list-item><p>Homepage: The primary interface of the WAFIR provides a user-centric platform for monitoring and managing daily hydration objectives. It enables patients to set personalized fluid consumption targets, log daily fluid intake, record urine output volumes, and visually assess urine color to determine hydration status.</p></list-item><list-item><p>Statistical Analysis page: This offers a comprehensive overview of patients&#x2019; hydration and urination patterns over multiple time frames. It presents historical data and trends in fluid intake and urine output, displayed on a daily, monthly, and annual basis. Through graphical visualizations, this module empowers patients and health care providers to monitor adherence trends, identify patterns, and adjust intervention strategies to optimize long-term compliance with fluid intake recommendations.</p></list-item><list-item><p>Health Education Knowledge page: The evidence-based materials tailored to kidney stone prevention are provided, which include detailed information on various types of UC and targeted prevention strategies. This is delivered through accessible formats like articles.</p></list-item><list-item><p>Function page: The applet will send notification messages at regular intervals, customized based on the patient&#x2019;s daily habits. The notification module delivers customized reminders designed to promote consistent fluid intake. By sending timely and context-relevant messages, the system encourages adherence to prescribed hydration regimens, addressing barriers such as forgetfulness or situational constraints.</p></list-item></list><p>The development of the WAFIR will begin with its registration on the WeChat Official Accounts platform, initiating a structured 6-phase development process as depicted in <xref ref-type="fig" rid="figure3">Figure 3</xref>. The first phase, WAFIR requirement analysis, will involve a multidisciplinary team&#x2014;including urological nurses, doctors, nursing education specialists, nutritionists, and postoperative patients with UC&#x2014;to conduct needs assessments, define functional specifications (eg, fluid intake reminders and urine output tracking), and develop evidence-based content through stakeholders&#x2019; feedback. The second phase will be the WAFIR design phase, where a user-friendly interface and function module will be created in collaboration with software developers and health care providers. The third phase of the WAFIR feasibility assessment will evaluate the prototype&#x2019;s technical performance and clinical utility through testing by the development team and clinical professionals. In the fourth phase, the WAFIR acceptability assessment will engage a cohort of 19 participants&#x2014;comprising 3 urological nurses, 3 urological doctors, 2 nursing education nurses, 1 nutritionist, and 10 postoperative patients&#x2014;to assess usability and collect feedback using validated tools such as the Mobile App Rating Scale [<xref ref-type="bibr" rid="ref29">29</xref>] and the mHealth Evidence Reporting and Assessment checklist [<xref ref-type="bibr" rid="ref30">30</xref>], ensuring that the WAFIR meets patient needs prior to the RCT. The fifth phase, monitoring and maintenance, will focus on ongoing improvements, incorporating user data and feedback to refine content and functionality. Finally, the clinical application phase will implement the fully validated WAFIR in real-world clinical settings for the RCT, aiming to enhance health management and prevention outcomes.</p><fig position="float" id="figure3"><label>Figure 3.</label><caption><p>Development of WAFIR flowchart. eHEALS: Electronic Health Literacy Scale; IPAQ-SF: International Physical Activity Questionnaire&#x2014;Short Form; PHQ-9: Patient Health Questionnaire-9; RCT: randomized controlled trial; WISQOL: Wisconsin Stone Quality of Life Questionnaire.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="resprot_v15i1e80214_fig03.png"/></fig></sec><sec id="s2-3-3"><title>Intervention Nurses</title><p>The principal investigator (XZ), a clinical nurse on the unit, will train the nursing team on the use of the WAFIR app. Nurses will be involved in securing informed consent from patients by interpreting the purpose, procedures, and anticipated benefits of the study and instructing patients how to use the WAFIR to log their fluid intake. Additionally, they will collect baseline and follow-up data through questionnaires at hospitalization and at 1-month and 3-month intervals. Physicians will evaluate and screen admitted patients to determine whether they meet the inclusion criteria for the research.</p></sec><sec id="s2-3-4"><title>Intervention Mechanism</title><p>The mechanism of the WAFIR provides a robust and constructive framework by providing a feedback loop, which is depicted in <xref ref-type="fig" rid="figure4">Figure 4</xref>, to enhance the adherence awareness of fluid intake for patients with UC, which is applied following these processes: goal setting to define the objective and specify the desired outcome: clearly define the water intake goals for patients, such as the amount of drink to be consumed at designated times; begin by establishing long-term and short-term goals. The long-term goal could be to prevent further formation of UC, while a short-term goal could be to ensure a specific amount of water intake per day. Action planning outlines a detailed process on how to achieve the set goals. This could involve developing a WeChat applet monitoring system to track each patient&#x2019;s water intake, deliver hydration reminders, formulate strategies to overcome barriers to hydration, provide educational documents, facilitate peer support from the community, and offer access to professional guidance. Essential training is also provided to ensure that patients are adept at using the WAFIR to manage and monitor their water intake. Self-monitoring of behavior: encourage patients to monitor their behavior, for instance, recording their daily water intake, the color of their urine, and the physical activity level they perform daily.</p><fig position="float" id="figure4"><label>Figure 4.</label><caption><p>The mechanism of WAFIR. WAFIR: WeChat-Based Applet Fluid Intake Reminder.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="resprot_v15i1e80214_fig04.png"/></fig><p>Concurrently, educating patients on the importance of proper hydration and its significant impact on health increases their intrinsic motivation. Nurses assist patients with behavioral skills development by setting reminders, recording water intake, and developing strategies to overcome barriers to hydration. Behavior feedback: the WAFIR incorporates feedback mechanisms to provide real-time feedback to patients. This is using notifications, alerts, or visual indicators to signal when patients&#x2019; hydration goals are not met. Data collected through the WAFIR are analyzed to recognize patterns of compliance and noncompliance, which help regulate behavior and reduce disparities between current and desired behaviors. This fosters self-monitoring and self-regulation through the WAFIR to enhance patients&#x2019; sense of self-efficacy for their drink intake. Goal review: regularly review the goals in light of the monitored behavior and feedback, which may involve adjusting the frequency of reminders, fluid intake goals, physical activity levels, dietary habits, or health literacy to align with patient behavior and feedback. This approach is supported by Partridge et al [<xref ref-type="bibr" rid="ref31">31</xref>], who demonstrated that mHealth interventions using techniques such as goal setting, self-monitoring of behavior, and feedback are more effective in promoting behavior modification than apps lacking these features. Similarly, a systematic review by Middelweerd et al [<xref ref-type="bibr" rid="ref32">32</xref>] evaluated 41 apps in iTunes and 23 apps in Google Play, identifying goal setting, self-monitoring, and feedback on performance as common approaches to promote intention to behavioral alteration.</p></sec></sec><sec id="s2-4"><title>Theory-Based Technique</title><p>Control theory examines how individuals monitor and modulate their behaviors to attain specific objectives. It underscores the importance of self-regulation, including behavior self-assessment, the establishment of targets, and the use of feedback mechanisms [<xref ref-type="bibr" rid="ref33">33</xref>]. Within the domain of health behaviors, control theory delineates the strategic adjustment of behaviors to fulfill health-related goals. Meanwhile, control theory, which comprises an input function, a comparator with reference values, an output function, an effect on the environment or others, and disturbance, is majorly applied to bridge the intention-behavior gap in artificial intelligence (AI) for physical action change. The detailed diagram described in <xref ref-type="fig" rid="figure5">Figure 5</xref> closely aligns with the WAFIR mechanism. The goal-setting and action-planning stages correspond to the input function and comparator phases; the self-monitoring of behavior and behavior feedback phases can be reflected in the output function; and the goal review stages can be found in the effects phase of the control theory, with disturbances identified accordingly.</p><fig position="float" id="figure5"><label>Figure 5.</label><caption><p>Control theory diagram.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="resprot_v15i1e80214_fig05.png"/></fig></sec><sec id="s2-5"><title>Ethical Considerations</title><p>This study received ethics approval from the University of Hong Kong/Hospital Authority Hong Kong West Cluster Ethics Review Board (UW24-754) and the Qianhai Shekou Free Trade Zone Hospital Ethics Committee (2024-055(Shen)-01) in December 2024. Written informed consent will be obtained from all participants, ensuring their right to withdraw, per the Declaration of Helsinki. Participant data will be deidentified, stored securely, and accessed only by authorized personnel to ensure privacy and confidentiality. The trial does not involve physical harm. No compensation will be provided, with voluntary participation incentivized by potential health benefits. No identifiable images or information will be included in the manuscript or supplementary materials. All procedures adhere to institutional and international ethical standards.</p></sec><sec id="s2-6"><title>Trial Registration</title><p>Our trial was retrospectively registered on ClinicalTrials.gov (NCT06990672) on May 24, 2025, after the initiation of recruitment. This delay was unintentional and resulted from unforeseen administrative challenges, including delays in securing institutional registration and coordinating with the tertiary hospital&#x2019;s research office in Mainland China, which were exacerbated by the rapid progression of the study timeline following the development of the WAFIR applet in February 2025. Recruitment commenced on March 1, 2025, and was completed by June 27, 2025, prior to registration, due to these logistical constraints. We affirm that this retrospective registration does not reflect an intent to bias reporting, as the study protocol, including design, outcomes, and intervention details, was finalized and documented internally before recruitment began, adhering to the original research plan.</p></sec><sec id="s2-7"><title>Outcome Measures</title><sec id="s2-7-1"><title>Primary Outcomes</title><sec id="s2-7-1-1"><title>24-Hour Urine Volume</title><p>To initiate the 24-hour urine collection, upon waking in the morning, void into a graduated container and document the precise start time (eg, 8 AM). On the subsequent morning, near the 24-hour end point (eg, 8 AM), we record the urine volume once more. Throughout this period, we use platforms such as the WeChat applet or alternative recording methods to track and document the cumulative urine output.</p></sec><sec id="s2-7-1-2"><title>24-Hour Fluid Intake Volume</title><p>This measure is to calculate the participants&#x2019; fluid intake for a full 24-hour period. This comprehensive record should span a full 24-hour period, ideally starting and ending at the same time of day to standardize the assessment. Participants will be instructed to record the fluid consumed using either the WAFIR or another recording method, including water, tea, coffee, Chinese herbal tea, and other eligible liquids. The data on daily fluid consumption volume can be summarized automatically once patients log the data in the WAFIR in the intervention group. However, the participants must manually report the fluid intake volume in the control group. This is the direct parameter that reflects the adherence to fluid intake in the WAFIR.</p></sec></sec></sec><sec id="s2-8"><title>Secondary Outcomes</title><sec id="s2-8-1"><title>Wisconsin Stone Quality of Life Questionnaire</title><p>Penniston et al [<xref ref-type="bibr" rid="ref34">34</xref>] developed the WISQOL as a disease-specific measure to assess the QoL of patients with UC. It encompasses 7 dimensions: vitality and fatigue, sleep, work and family, nutrition (diet) and pharmacotherapy, physical conditions, concerns over intimacy and traveling, and emotional status in general [<xref ref-type="bibr" rid="ref34">34</xref>]. The scale consists of 28 items, each rated on a 5-point scale from 1=very true to 5=not at all true, yielding a total score range between 28 and 140. A higher score indicates a better QoL. This scale is widely used in multicenter studies in various countries, such as the United States and Canada, for its well-confirmed reliability and validity. Cronbach &#x03B1; coefficient was 0.948, and the reliability was 0.907 in the Chinese version.</p></sec><sec id="s2-8-2"><title>Patient Health Questionnaire-9</title><p>This assesses participants&#x2019; mental health status after receiving different interventions, which can help monitor the health status and psychological well-being of patients [<xref ref-type="bibr" rid="ref35">35</xref>]. Nine items with a cumulative score on the Patient Health Questionnaire-9 (PHQ-9) range from 0 to 27. Cronbach &#x03B1; coefficient was 0.839, and the reliability was 0.846 in the Chinese version.</p></sec><sec id="s2-8-3"><title>International Physical Activity Questionnaire&#x2014;Short Form</title><p>This assesses the participants&#x2019; physical activity levels and the frequency and duration of the workout [<xref ref-type="bibr" rid="ref36">36</xref>], which can affect the fluid requirements and the risk of UC formation. The questionnaire consists of 7 questions to assess physical activity level over the past week. Activity is classified as low if the total score is &#x003C;600 metabolic equivalent of task-minutes per week and classified as high if it is &#x003E;3000 metabolic equivalent of task-minutes per week. The intraclass correlation coefficients for all physical activity categories within the International Physical Activity Questionnaire were above 0.7 in the Chinese version.</p></sec><sec id="s2-8-4"><title>Electronic Health Literacy Scale</title><p>This scale is designed by Norman and Skinner [<xref ref-type="bibr" rid="ref37">37</xref>] to measure an individual&#x2019;s self-perceived skills in using information technology for seeking, searching, understanding, and appraising health information from electronic sources. Including 8 items with a 5-point Likert scale, the total score ranges from 8 to 40. The Cronbach &#x03B1; coefficient of the eHEALS scale is 0.963. The retest reliability coefficient <italic>r</italic> was 0.984 (<italic>P</italic>&#x003C;.001) in the Chinese version.</p></sec><sec id="s2-8-5"><title>The Number of Readmissions, Outpatient Visits, and Emergency Department Visits</title><p>This assesses the frequency of hospital readmissions related to UC, including the timing of such readmissions due to stone recurrence or related symptoms (eg, hematuria, pain, and infection) and the number of outpatient visits in terms of UC management. The frequency of emergency department visits is due to UC. Any medications might affect fluid intake or urinary output or improve the symptoms that triggered postoperatively.</p></sec><sec id="s2-8-6"><title>Recurrence Rate</title><p>The rate at which new UC forms during the 3-month follow-up.</p></sec><sec id="s2-8-7"><title>Frequency of Hematuria or Dark Urine</title><p>The frequency of the presence of blood in urine or dark urine, which can be a symptom of a new urinary stone or a signal of less fluid intake.</p></sec></sec><sec id="s2-9"><title>Sample Size</title><p>An adequate sample size and statistical power ensure that the findings can be reliably generalized to a broader population. The required sample size for hypothesis testing is determined based on the expected effect size [<xref ref-type="bibr" rid="ref38">38</xref>]. In this study, the sample size will be determined by a statistical tool, G*Power software (Heinrich Heine University D&#x00FC;sseldorf) [<xref ref-type="bibr" rid="ref39">39</xref>], with an &#x03B1; of .05, a power of 0.80, and an allocation ratio of 1:1. The sample size for this study was calculated based on a comparable RCT that used an eHealth device (an intelligent water bottle) to promote increased fluid intake [<xref ref-type="bibr" rid="ref18">18</xref>], of which the calculated Cohen <italic>d</italic> was 0.61, and the effect size is considered significant since Cohen <italic>d</italic> is over 0.5. Based on the calculations, a sample size of 92 participants is estimated. Accounting for an attrition rate of 38%, as observed in this research, a total of 148 participants are anticipated to be recruited.</p></sec><sec id="s2-10"><title>Randomization, Blinding, and Concealed Allocation</title><p>An RCT will be conducted to recruit participants in a single site, the Shekou Free Trade Zone Hospital. Randomization may lead to baseline characteristic imbalances between intervention groups [<xref ref-type="bibr" rid="ref40">40</xref>]. In small-scale trials, stratification might be beneficial, as it can prevent significant imbalances in factors predicting outcomes [<xref ref-type="bibr" rid="ref41">41</xref>]. Stratified randomization will be applied to the eligible participants to ensure an equal chance to be allocated to the research field [<xref ref-type="bibr" rid="ref42">42</xref>]. Balanced randomization aims to create unbiased groups for comparison and also seeks to maintain groups of roughly equivalent size throughout the trial [<xref ref-type="bibr" rid="ref43">43</xref>]. In this research, convenience sampling will be applied, with block randomization applied using a block size of 10. For every group of 10 participants enrolled in sequence, 5 will be allocated to the intervention group and the remaining 5 to the control group, which will be done by the statistician and urologists who are not engaged in conducting the research interventions.</p></sec><sec id="s2-11"><title>Data Collection</title><p>The study will be conducted on postoperative patients with UC. It will span 3 periods: T0 (before the intervention), T1 (at the end of 1 month), and T2 (at the end of 3 months). The data collected at each time point will allow for evaluating the intervention&#x2019;s effectiveness and identifying areas for improvement. Reminders will be sent prior to each follow-up visit using the participant&#x2019;s preferred method of communication, with a thank-you message after the visit. For any participant who discontinues the intervention prematurely, we will record the reason for their discontinuation and collect any serious adverse events that occurred up to the point of discontinuation.</p></sec><sec id="s2-12"><title>Methods of Analysis</title><p>The study outcomes will be reported to adhere to the guidelines outlined in the CONSORT (Consolidated Standards of Reporting Trials) 2010 statements [<xref ref-type="bibr" rid="ref44">44</xref>]. Statistical tests such as a 2-tailed <italic>t</italic> test and chi-square test will be used for continuous and categorical variables within 2 groups. The principal analysis will compare the fluid intake volume between the intervention and control groups using the 2-tailed <italic>t</italic> test. Secondary outcomes such as WISQOL, PHQ-9, and eHEALS will use repeated measures of ANOVA since they are measured over time and between 2 groups. If necessary, subgroup analyses will be conducted to explore whether the effect of the intervention varies across different demographic or clinical subgroups. Intention-to-treat analysis will be used to assess the impact of the treatment and its generalizability as well as the missing data. A planned interim analysis will be performed to evaluate both efficacy (whether the intervention shows sufficient benefit to potentially stop the trial early) and futility (whether the intervention is unlikely to demonstrate benefit if the trial continues) after 50% (74/148) of the target sample size have completed the primary end-point assessment. A significance level of <italic>P</italic>&#x003C;.05 will be used to determine statistical significance, and all data analysis procedures will be conducted using the SPSS (version 26.0; IBM Corp) software package.</p></sec><sec id="s2-13"><title>Access to Data</title><p>The researcher is granted access to the complete trial dataset, with a contractual agreement established with the statistician to manage the data confidentially in accordance with the research protocol.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>This research has achieved notable advancements in assessing the efficacy of a nurse-led digital health intervention, WAFIR. The development of WAFIR, conducted in collaboration with a software developer, was finalized in February 2025, establishing a technological platform for the study. Recruitment, a critical initial stage, was fully completed, with all 148 participants enrolled from a tertiary hospital in Mainland China between March 1, 2025, and June 27, 2025, exclusively during the predischarge hospitalization period. Baseline data collection (T0) was completed by June 30, 2025, providing a solid baseline for longitudinal analysis. Follow-up assessments at the 1-month mark (T1) were finalized on July 31, 2025, while the 3-month follow-up (T2) is set to conclude in October 2025, aligning with the present date. Subsequent data analysis is scheduled for completion by December 2025, with dissemination of results planned through academic conferences and peer-reviewed publications throughout 2026.</p></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>This study represents, to our knowledge, one of the first RCTs to assess a nurse-led, WeChat-based DTx specifically tailored for UC management, addressing a critical gap in mHealth interventions that often lack medical oversight or clinical validation. The primary outcomes of this study are to evaluate the effectiveness of the WAFIR in improving fluid intake and urine output among postoperative patients with UC. We hypothesize that the WAFIR intervention, combining fluid intake reminders, urine color monitoring, fluid and urine tracking, and evidence-based educational content, will significantly enhance adherence to hydration recommendations compared to standard care, potentially lowering recurrence rates and improving patient-reported outcomes such as QoL (via WISQOL), eHealth literacy (via eHEALS), and mental health (via PHQ-9).</p><p>This study used face-to-face and telephone interviews to collect data. However, interviews are subject to limitations, including the absence of visual cues (particularly in telephone interviews), reduced ability to observe contextual details, and potential difficulties in eliciting sensitive information, which may affect data quality [<xref ref-type="bibr" rid="ref45">45</xref>]. The primary outcome, 24-hour urine volume, is required to be collected. However, previous studies indicate challenges in obtaining precise 24-hour urine samples due to poor patient compliance, which may result in incomplete or abandoned collections stemming from the complex or inconvenient nature of the process, as well as deviations from the 24-hour collection period. To enhance the measurement accuracy of 24-hour urine collection, it is crucial to improve patient education on the importance of urine collection; simplify the collection process with clear guidelines, flowcharts, and user-friendly containers; and provide necessary tools like graduated urinals or collection bags. Regular monitoring and feedback sessions are essential to address any issues promptly. Additionally, incentivizing participation with rewards can boost patient motivation, ensuring higher compliance and accurate urine volume measurements within the specified time frame.</p><p>A key strength of this study is its rigorous RCT design, with clear inclusion criteria, randomization, and intention-to-treat analysis, ensuring robust evidence generation. However, there are several limitations to this protocol that should be acknowledged. First, patients were recruited from a single site. This limitation may affect the generalizability of the findings, as the sample may not be representative of the broader population. Second, the current WAFIR is equipped with a fluid record function, evidence-based educational content delivery, automated reminders and notifications, and data collection and reporting. AI technologies, such as AI-driven predictive models, are not equipped within the WAFIR, as the integration could enhance its effectiveness by providing tailored health education, motivational messages, and personalized recommendations based on individual patient data and behavior patterns.</p><p>The dissemination plan includes presenting research findings at international conferences and forums and publishing in peer-reviewed journals in 2026. If proven effective, WAFIR could establish a pathway for developing other nurse-led digital interventions, offering a low-cost and scalable approach to enhance patient outcomes in chronic disease management. Furthermore, the findings will guide app developers in creating clinically validated mHealth tools and assist clinicians in integrating such interventions into standard urolithiasis care, thereby potentially transforming postoperative management practices.</p></sec></body><back><ack><p>The authors would like to thank He Ruoying for her valuable assistance with the sample size calculations and certain statistical aspects of the research. The authors disclose that generative artificial intelligence (specifically, ChatGPT or DeepSeek or QuillBot) was used during the preparation of this manuscript. The tool was used solely for the purpose of improving the language and readability of the text.</p></ack><notes><sec><title>Funding</title><p>No external financial support or grants were received from any public, commercial, or not-for-profit entities for the research, authorship, or publication of this paper.</p></sec><sec><title>Data Availability</title><p>The datasets generated and/or analyzed will not be publicly available due to privacy and ethical restrictions. However, requests for data access will be considered on an individual basis by contacting the corresponding author.</p></sec></notes><fn-group><fn fn-type="con"><p>XZ and TW conceptualized the research design and developed the WeChat-based digital therapeutic intervention, and TW led the protocol development, statistical planning, and the ethical considerations for the randomized controlled trial. XZ drafted the initial manuscript. QC coordinated participant recruitment strategies, ensuring the effective enrollment of patients with urinary calculi. All authors (XZ, TW, and QC) critically reviewed, drafted, and approved the final manuscript and agree to be accountable for all aspects of the work, ensuring its accuracy and integrity.</p></fn><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">AI</term><def><p>artificial intelligence</p></def></def-item><def-item><term id="abb2">CONSORT</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term id="abb3">DTx</term><def><p>digital therapeutic intervention</p></def></def-item><def-item><term id="abb4">eHEALS</term><def><p>Electronic Health Literacy Scale</p></def></def-item><def-item><term id="abb5">mHealth</term><def><p>mobile health</p></def></def-item><def-item><term id="abb6">PHQ-9</term><def><p>Patient Health Questionnaire-9</p></def></def-item><def-item><term id="abb7">QoL</term><def><p>quality of life</p></def></def-item><def-item><term id="abb8">RCT </term><def><p>randomized controlled trial</p></def></def-item><def-item><term id="abb9">UC</term><def><p>urinary calculi</p></def></def-item><def-item><term id="abb10">WAFIR</term><def><p>WeChat-Based Applet Fluid Intake Reminder</p></def></def-item><def-item><term id="abb11">WISQOL </term><def><p>Wisconsin Stone Quality of Life Questionnaire</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafi</surname><given-names>H</given-names> </name><name name-style="western"><surname>Moazzami</surname><given-names>B</given-names> </name><name name-style="western"><surname>Pourghasem</surname><given-names>M</given-names> </name><name name-style="western"><surname>Kasaeian</surname><given-names>A</given-names> </name></person-group><article-title>An overview of treatment options for urinary stones</article-title><source>Caspian J Intern Med</source><year>2016</year><volume>7</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="medline">26958325</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorokin</surname><given-names>I</given-names> </name><name name-style="western"><surname>Mamoulakis</surname><given-names>C</given-names> </name><name name-style="western"><surname>Miyazawa</surname><given-names>K</given-names> </name><name name-style="western"><surname>Rodgers</surname><given-names>A</given-names> </name><name name-style="western"><surname>Talati</surname><given-names>J</given-names> </name><name name-style="western"><surname>Lotan</surname><given-names>Y</given-names> </name></person-group><article-title>Epidemiology of stone disease across the world</article-title><source>World J Urol</source><year>2017</year><month>09</month><volume>35</volume><issue>9</issue><fpage>1301</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1007/s00345-017-2008-6</pub-id><pub-id pub-id-type="medline">28213860</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero</surname><given-names>V</given-names> </name><name name-style="western"><surname>Akpinar</surname><given-names>H</given-names> </name><name name-style="western"><surname>Assimos</surname><given-names>DG</given-names> </name></person-group><article-title>Kidney stones: a global picture of prevalence, incidence, and associated risk factors</article-title><source>Rev Urol</source><year>2010</year><volume>12</volume><issue>2-3</issue><fpage>e86</fpage><lpage>96</lpage><pub-id pub-id-type="medline">20811557</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>G</given-names> </name><name name-style="western"><surname>Mai</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Xia</surname><given-names>S</given-names> </name><etal/></person-group><article-title>Prevalence of kidney stones in China: an ultrasonography based cross-sectional study</article-title><source>BJU Int</source><year>2017</year><month>07</month><volume>120</volume><issue>1</issue><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1111/bju.13828</pub-id><pub-id pub-id-type="medline">28236332</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>CM</given-names> </name><name name-style="western"><surname>Wilson</surname><given-names>DM</given-names> </name><name name-style="western"><surname>O&#x2019;Fallon</surname><given-names>WM</given-names> </name><name name-style="western"><surname>Malek</surname><given-names>RS</given-names> </name><name name-style="western"><surname>Kurland</surname><given-names>LT</given-names> </name></person-group><article-title>Renal stone epidemiology: a 25-year study in Rochester, Minnesota</article-title><source>Kidney Int</source><year>1979</year><month>11</month><volume>16</volume><issue>5</issue><fpage>624</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1038/ki.1979.173</pub-id><pub-id pub-id-type="medline">548606</pub-id></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearle</surname><given-names>MS</given-names> </name><name name-style="western"><surname>Calhoun</surname><given-names>EA</given-names> </name><name name-style="western"><surname>Curhan</surname><given-names>GC</given-names> </name><collab>Urologic Diseases of America Project</collab></person-group><article-title>Urologic diseases in America project: urolithiasis</article-title><source>J Urol</source><year>2005</year><month>03</month><volume>173</volume><issue>3</issue><fpage>848</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000152082.14384.d7</pub-id><pub-id pub-id-type="medline">15711292</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moftakhar</surname><given-names>L</given-names> </name><name name-style="western"><surname>Jafari</surname><given-names>F</given-names> </name><name name-style="western"><surname>Ghoddusi Johari</surname><given-names>M</given-names> </name><name name-style="western"><surname>Rezaeianzadeh</surname><given-names>R</given-names> </name><name name-style="western"><surname>Hosseini</surname><given-names>SV</given-names> </name><name name-style="western"><surname>Rezaianzadeh</surname><given-names>A</given-names> </name></person-group><article-title>Prevalence and risk factors of kidney stone disease in population aged 40-70 years old in Kharameh cohort study: a cross-sectional population-based study in southern Iran</article-title><source>BMC Urol</source><year>2022</year><month>12</month><day>19</day><volume>22</volume><issue>1</issue><fpage>205</fpage><pub-id pub-id-type="doi">10.1186/s12894-022-01161-x</pub-id><pub-id pub-id-type="medline">36536352</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becerra</surname><given-names>AZ</given-names> </name><name name-style="western"><surname>Khusid</surname><given-names>JA</given-names> </name><name name-style="western"><surname>Sturgis</surname><given-names>MR</given-names> </name><etal/></person-group><article-title>Contemporary assessment of the economic burden of upper urinary tract stone disease in the United States: analysis of one-year health care costs, 2011-2018</article-title><source>J Endourol</source><year>2022</year><month>04</month><volume>36</volume><issue>4</issue><fpage>429</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1089/end.2021.0485</pub-id><pub-id pub-id-type="medline">34693752</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lotan</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Buendia Jim&#x00E9;nez</surname><given-names>I</given-names> </name><name name-style="western"><surname>Lenoir&#x2010;Wijnkoop</surname><given-names>I</given-names> </name><etal/></person-group><article-title>Primary prevention of nephrolithiasis is cost&#x2010;effective for a national healthcare system</article-title><source>BJU Int</source><year>2012</year><month>12</month><volume>110</volume><issue>11c</issue><fpage>E1060</fpage><lpage>E1067</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11212.x</pub-id></nlm-citation></ref><ref id="ref10"><label>10</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fakheri</surname><given-names>RJ</given-names> </name><name name-style="western"><surname>Goldfarb</surname><given-names>DS</given-names> </name></person-group><article-title>Ambient temperature as a contributor to kidney stone formation: implications of global warming</article-title><source>Kidney Int</source><year>2011</year><month>06</month><volume>79</volume><issue>11</issue><fpage>1178</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.76</pub-id><pub-id pub-id-type="medline">21451456</pub-id></nlm-citation></ref><ref id="ref11"><label>11</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitra</surname><given-names>P</given-names> </name><name name-style="western"><surname>Pal</surname><given-names>DK</given-names> </name><name name-style="western"><surname>Das</surname><given-names>M</given-names> </name></person-group><article-title>Does quality of drinking water matter in kidney stone disease: a study in West Bengal, India</article-title><source>Investig Clin Urol</source><year>2018</year><month>05</month><volume>59</volume><issue>3</issue><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.4111/icu.2018.59.3.158</pub-id><pub-id pub-id-type="medline">29744472</pub-id></nlm-citation></ref><ref id="ref12"><label>12</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathiyalagen</surname><given-names>P</given-names> </name><name name-style="western"><surname>Neelakantan</surname><given-names>A</given-names> </name><name name-style="western"><surname>Balusamy</surname><given-names>K</given-names> </name><name name-style="western"><surname>Vasudevan</surname><given-names>K</given-names> </name><name name-style="western"><surname>Cherian</surname><given-names>J</given-names> </name><name name-style="western"><surname>Sunderamurthy</surname><given-names>B</given-names> </name></person-group><article-title>A case-control study on environmental and biological risk factors for renal calculi persisting in a coastal Union Territory, India</article-title><source>J Family Med Prim Care</source><year>2017</year><volume>6</volume><issue>1</issue><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.4103/2249-4863.214981</pub-id><pub-id pub-id-type="medline">29026764</pub-id></nlm-citation></ref><ref id="ref13"><label>13</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferraro</surname><given-names>PM</given-names> </name><name name-style="western"><surname>Bargagli</surname><given-names>M</given-names> </name><name name-style="western"><surname>Trinchieri</surname><given-names>A</given-names> </name><name name-style="western"><surname>Gambaro</surname><given-names>G</given-names> </name></person-group><article-title>Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian-vegan diets</article-title><source>Nutrients</source><year>2020</year><month>03</month><day>15</day><volume>12</volume><issue>3</issue><fpage>779</fpage><pub-id pub-id-type="doi">10.3390/nu12030779</pub-id><pub-id pub-id-type="medline">32183500</pub-id></nlm-citation></ref><ref id="ref14"><label>14</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheraghian</surname><given-names>B</given-names> </name><name name-style="western"><surname>Meysam</surname><given-names>A</given-names> </name><name name-style="western"><surname>Hashemi</surname><given-names>SJ</given-names> </name><etal/></person-group><article-title>Kidney stones and dietary intake in adults: a population-based study in southwest Iran</article-title><source>BMC Public Health</source><year>2024</year><month>04</month><day>4</day><volume>24</volume><issue>1</issue><fpage>955</fpage><pub-id pub-id-type="doi">10.1186/s12889-024-18393-1</pub-id><pub-id pub-id-type="medline">38575950</pub-id></nlm-citation></ref><ref id="ref15"><label>15</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Streeper</surname><given-names>NM</given-names> </name><name name-style="western"><surname>Dubnansky</surname><given-names>A</given-names> </name><name name-style="western"><surname>Sanders</surname><given-names>AB</given-names> </name><name name-style="western"><surname>Lehman</surname><given-names>K</given-names> </name><name name-style="western"><surname>Thomaz</surname><given-names>E</given-names> </name><name name-style="western"><surname>Conroy</surname><given-names>DE</given-names> </name></person-group><article-title>Improving fluid intake behavior among patients with kidney stones: understanding patients&#x2019; experiences and acceptability of digital health technology</article-title><source>Urology</source><year>2019</year><month>11</month><volume>133</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2019.05.056</pub-id><pub-id pub-id-type="medline">31374289</pub-id></nlm-citation></ref><ref id="ref16"><label>16</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCauley</surname><given-names>LR</given-names> </name><name name-style="western"><surname>Dyer</surname><given-names>AJ</given-names> </name><name name-style="western"><surname>Stern</surname><given-names>K</given-names> </name><name name-style="western"><surname>Hicks</surname><given-names>T</given-names> </name><name name-style="western"><surname>Nguyen</surname><given-names>MM</given-names> </name></person-group><article-title>Factors influencing fluid intake behavior among kidney stone formers</article-title><source>J Urol</source><year>2012</year><month>04</month><volume>187</volume><issue>4</issue><fpage>1282</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2011.11.111</pub-id><pub-id pub-id-type="medline">22341296</pub-id></nlm-citation></ref><ref id="ref17"><label>17</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khambati</surname><given-names>A</given-names> </name><name name-style="western"><surname>Matulewicz</surname><given-names>RS</given-names> </name><name name-style="western"><surname>Perry</surname><given-names>KT</given-names> </name><name name-style="western"><surname>Nadler</surname><given-names>RB</given-names> </name></person-group><article-title>Factors associated with compliance to increased fluid intake and urine volume following dietary counseling in first-time kidney stone patients</article-title><source>J Endourol</source><year>2017</year><month>06</month><volume>31</volume><issue>6</issue><fpage>605</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1089/end.2016.0836</pub-id><pub-id pub-id-type="medline">28318298</pub-id></nlm-citation></ref><ref id="ref18"><label>18</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stout</surname><given-names>TE</given-names> </name><name name-style="western"><surname>Lingeman</surname><given-names>JE</given-names> </name><name name-style="western"><surname>Krambeck</surname><given-names>AE</given-names> </name><etal/></person-group><article-title>A randomized trial evaluating the use of a smart water bottle to increase fluid intake in stone formers</article-title><source>J Ren Nutr</source><year>2022</year><month>07</month><volume>32</volume><issue>4</issue><fpage>389</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1053/j.jrn.2021.07.007</pub-id><pub-id pub-id-type="medline">35283036</pub-id></nlm-citation></ref><ref id="ref19"><label>19</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tasian</surname><given-names>GE</given-names> </name><name name-style="western"><surname>Ross</surname><given-names>M</given-names> </name><name name-style="western"><surname>Song</surname><given-names>L</given-names> </name><etal/></person-group><article-title>Ecological momentary assessment of factors associated with water intake among adolescents with kidney stone disease</article-title><source>J Urol</source><year>2019</year><month>03</month><volume>201</volume><issue>3</issue><fpage>606</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2018.07.064</pub-id><pub-id pub-id-type="medline">30076905</pub-id></nlm-citation></ref><ref id="ref20"><label>20</label><nlm-citation citation-type="web"><article-title>DTA&#x2019;s adoption &#x0026; interpretation of ISO&#x2019;s DTx definition</article-title><source>Digital Therapeutics Alliance</source><year>2023</year><access-date>2026-02-11</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://dtxalliance.org/wp-content/uploads/2023/06/DTA_FS_New-DTx-Definition.pdf">https://dtxalliance.org/wp-content/uploads/2023/06/DTA_FS_New-DTx-Definition.pdf</ext-link></comment></nlm-citation></ref><ref id="ref21"><label>21</label><nlm-citation citation-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Ceci</surname><given-names>L</given-names> </name></person-group><article-title>Number of apps available in leading app stores</article-title><source>Statista</source><year>2026</year><month>01</month><day>13</day><access-date>2026-02-06</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.statista.com/statistics/276623/number-of-apps-available-in-leading-app-stores/">https://www.statista.com/statistics/276623/number-of-apps-available-in-leading-app-stores/</ext-link></comment></nlm-citation></ref><ref id="ref22"><label>22</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names> </name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names> </name><name name-style="western"><surname>Li</surname><given-names>D</given-names> </name><etal/></person-group><article-title>The establishment and practice of pharmacy care service based on internet social media: telemedicine in response to the COVID-19 pandemic</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>707442</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.707442</pub-id></nlm-citation></ref><ref id="ref23"><label>23</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Li</surname><given-names>N</given-names> </name><name name-style="western"><surname>Li</surname><given-names>D</given-names> </name><etal/></person-group><article-title>Telemedicine during the COVID-19 pandemic: experiences from Western China</article-title><source>J Med Internet Res</source><year>2020</year><month>05</month><day>8</day><volume>22</volume><issue>5</issue><fpage>e19577</fpage><pub-id pub-id-type="doi">10.2196/19577</pub-id><pub-id pub-id-type="medline">32349962</pub-id></nlm-citation></ref><ref id="ref24"><label>24</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names> </name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names> </name><name name-style="western"><surname>Li</surname><given-names>H</given-names> </name><name name-style="western"><surname>Li</surname><given-names>J</given-names> </name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names> </name></person-group><article-title>The value of WeChat application in chronic diseases management in China</article-title><source>Comput Methods Programs Biomed</source><year>2020</year><month>11</month><volume>196</volume><fpage>105710</fpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2020.105710</pub-id><pub-id pub-id-type="medline">32858284</pub-id></nlm-citation></ref><ref id="ref25"><label>25</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>DJ</given-names> </name><name name-style="western"><surname>McKenzie</surname><given-names>K</given-names> </name><name name-style="western"><surname>Cui</surname><given-names>HW</given-names> </name><name name-style="western"><surname>Noble</surname><given-names>JG</given-names> </name><name name-style="western"><surname>Turney</surname><given-names>BW</given-names> </name></person-group><article-title>Smartphone apps for urolithiasis</article-title><source>Urolithiasis</source><year>2015</year><month>02</month><volume>43</volume><issue>1</issue><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/s00240-014-0738-0</pub-id><pub-id pub-id-type="medline">25410731</pub-id></nlm-citation></ref><ref id="ref26"><label>26</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karag&#x00F6;z</surname><given-names>MA</given-names> </name><name name-style="western"><surname>Sar&#x0131;ca</surname><given-names>K</given-names> </name></person-group><article-title>Patient compliance to dietary recommendations: tips and tricks to improve compliance rates</article-title><source>World J Urol</source><year>2023</year><month>05</month><volume>41</volume><issue>5</issue><fpage>1261</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1007/s00345-023-04318-x</pub-id><pub-id pub-id-type="medline">36786816</pub-id></nlm-citation></ref><ref id="ref27"><label>27</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philip-McKenzie</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Jamnadass</surname><given-names>E</given-names> </name><name name-style="western"><surname>Hameed</surname><given-names>BZ</given-names> </name><etal/></person-group><article-title>A content analysis of &#x201C;Water Apps&#x201D; and prevention of urological diseases: do apps really help?</article-title><source>Cent Eur J Urol</source><year>2020</year><volume>73</volume><issue>2</issue><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.5173/ceju.2020.0136</pub-id><pub-id pub-id-type="medline">32782839</pub-id></nlm-citation></ref><ref id="ref28"><label>28</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winoker</surname><given-names>JS</given-names> </name><name name-style="western"><surname>Koo</surname><given-names>K</given-names> </name><name name-style="western"><surname>Matlaga</surname><given-names>BR</given-names> </name></person-group><article-title>Barriers to the adoption and integration of patient-facing mHealth tools in urology</article-title><source>Nat Rev Urol</source><year>2021</year><month>05</month><volume>18</volume><issue>5</issue><fpage>247</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1038/s41585-021-00444-6</pub-id><pub-id pub-id-type="medline">33692501</pub-id></nlm-citation></ref><ref id="ref29"><label>29</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoyanov</surname><given-names>SR</given-names> </name><name name-style="western"><surname>Hides</surname><given-names>L</given-names> </name><name name-style="western"><surname>Kavanagh</surname><given-names>DJ</given-names> </name><name name-style="western"><surname>Zelenko</surname><given-names>O</given-names> </name><name name-style="western"><surname>Tjondronegoro</surname><given-names>D</given-names> </name><name name-style="western"><surname>Mani</surname><given-names>M</given-names> </name></person-group><article-title>Mobile app rating scale: a new tool for assessing the quality of health mobile apps</article-title><source>JMIR Mhealth Uhealth</source><year>2015</year><month>03</month><day>11</day><volume>3</volume><issue>1</issue><fpage>e27</fpage><pub-id pub-id-type="doi">10.2196/mhealth.3422</pub-id><pub-id pub-id-type="medline">25760773</pub-id></nlm-citation></ref><ref id="ref30"><label>30</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>S</given-names> </name><name name-style="western"><surname>LeFevre</surname><given-names>AE</given-names> </name><name name-style="western"><surname>Lee</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist</article-title><source>BMJ</source><year>2016</year><month>03</month><day>17</day><volume>352</volume><fpage>i1174</fpage><pub-id pub-id-type="doi">10.1136/bmj.i1174</pub-id><pub-id pub-id-type="medline">26988021</pub-id></nlm-citation></ref><ref id="ref31"><label>31</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Partridge</surname><given-names>SR</given-names> </name><name name-style="western"><surname>McGeechan</surname><given-names>K</given-names> </name><name name-style="western"><surname>Hebden</surname><given-names>L</given-names> </name><etal/></person-group><article-title>Effectiveness of a mHealth lifestyle program with telephone support (TXT2BFiT) to prevent unhealthy weight gain in young adults: randomized controlled trial</article-title><source>JMIR Mhealth Uhealth</source><year>2015</year><month>06</month><day>15</day><volume>3</volume><issue>2</issue><fpage>e66</fpage><pub-id pub-id-type="doi">10.2196/mhealth.4530</pub-id><pub-id pub-id-type="medline">26076688</pub-id></nlm-citation></ref><ref id="ref32"><label>32</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middelweerd</surname><given-names>A</given-names> </name><name name-style="western"><surname>Mollee</surname><given-names>JS</given-names> </name><name name-style="western"><surname>van der Wal</surname><given-names>CN</given-names> </name><name name-style="western"><surname>Brug</surname><given-names>J</given-names> </name><name name-style="western"><surname>Te Velde</surname><given-names>SJ</given-names> </name></person-group><article-title>Apps to promote physical activity among adults: a review and content analysis</article-title><source>Int J Behav Nutr Phys Act</source><year>2014</year><month>07</month><day>25</day><volume>11</volume><issue>1</issue><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/s12966-014-0097-9</pub-id><pub-id pub-id-type="medline">25059981</pub-id></nlm-citation></ref><ref id="ref33"><label>33</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carver</surname><given-names>CS</given-names> </name><name name-style="western"><surname>Scheier</surname><given-names>MF</given-names> </name></person-group><article-title>Control theory: a useful conceptual framework for personality-social, clinical, and health psychology</article-title><source>Psychol Bull</source><year>1982</year><month>07</month><volume>92</volume><issue>1</issue><fpage>111</fpage><lpage>135</lpage><pub-id pub-id-type="medline">7134324</pub-id></nlm-citation></ref><ref id="ref34"><label>34</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penniston</surname><given-names>KL</given-names> </name><name name-style="western"><surname>Antonelli</surname><given-names>JA</given-names> </name><name name-style="western"><surname>Viprakasit</surname><given-names>DP</given-names> </name><etal/></person-group><article-title>Validation and reliability of the Wisconsin Stone Quality of Life Questionnaire</article-title><source>J Urol</source><year>2017</year><month>05</month><volume>197</volume><issue>5</issue><fpage>1280</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2016.11.097</pub-id><pub-id pub-id-type="medline">27889419</pub-id></nlm-citation></ref><ref id="ref35"><label>35</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroenke</surname><given-names>K</given-names> </name><name name-style="western"><surname>Spitzer</surname><given-names>RL</given-names> </name><name name-style="western"><surname>Williams</surname><given-names>JB</given-names> </name></person-group><article-title>The PHQ-9: validity of a brief depression severity measure</article-title><source>J Gen Intern Med</source><year>2001</year><month>09</month><volume>16</volume><issue>9</issue><fpage>606</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1497.2001.016009606.x</pub-id><pub-id pub-id-type="medline">11556941</pub-id></nlm-citation></ref><ref id="ref36"><label>36</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craig</surname><given-names>CL</given-names> </name><name name-style="western"><surname>Marshall</surname><given-names>AL</given-names> </name><name name-style="western"><surname>Sj&#x00F6;str&#x00F6;m</surname><given-names>M</given-names> </name><etal/></person-group><article-title>International Physical Activity Questionnaire: 12-country reliability and validity</article-title><source>Med Sci Sports Exerc</source><year>2003</year><month>08</month><volume>35</volume><issue>8</issue><fpage>1381</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1249/01.MSS.0000078924.61453.FB</pub-id></nlm-citation></ref><ref id="ref37"><label>37</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norman</surname><given-names>CD</given-names> </name><name name-style="western"><surname>Skinner</surname><given-names>HA</given-names> </name></person-group><article-title>eHEALS: The eHealth Literacy Scale</article-title><source>J Med Internet Res</source><year>2006</year><month>11</month><day>14</day><volume>8</volume><issue>4</issue><fpage>e27</fpage><pub-id pub-id-type="doi">10.2196/jmir.8.4.e27</pub-id><pub-id pub-id-type="medline">17213046</pub-id></nlm-citation></ref><ref id="ref38"><label>38</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ialongo</surname><given-names>C</given-names> </name></person-group><article-title>Understanding the effect size and its measures</article-title><source>Biochem Med (Zagreb)</source><year>2016</year><volume>26</volume><issue>2</issue><fpage>150</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.11613/BM.2016.015</pub-id><pub-id pub-id-type="medline">27346958</pub-id></nlm-citation></ref><ref id="ref39"><label>39</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faul</surname><given-names>F</given-names> </name><name name-style="western"><surname>Erdfelder</surname><given-names>E</given-names> </name><name name-style="western"><surname>Lang</surname><given-names>AG</given-names> </name><name name-style="western"><surname>Buchner</surname><given-names>A</given-names> </name></person-group><article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behav Res Methods</source><year>2007</year><month>05</month><volume>39</volume><issue>2</issue><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/bf03193146</pub-id><pub-id pub-id-type="medline">17695343</pub-id></nlm-citation></ref><ref id="ref40"><label>40</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altman</surname><given-names>DG</given-names> </name><name name-style="western"><surname>Schulz</surname><given-names>KF</given-names> </name><name name-style="western"><surname>Moher</surname><given-names>D</given-names> </name><etal/></person-group><article-title>The revised CONSORT statement for reporting randomized trials: explanation and elaboration</article-title><source>Ann Intern Med</source><year>2001</year><month>04</month><day>17</day><volume>134</volume><issue>8</issue><fpage>663</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-134-8-200104170-00012</pub-id><pub-id pub-id-type="medline">11304107</pub-id></nlm-citation></ref><ref id="ref41"><label>41</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>KF</given-names> </name><name name-style="western"><surname>Grimes</surname><given-names>DA</given-names> </name></person-group><article-title>Generation of allocation sequences in randomised trials: chance, not choice</article-title><source>Lancet</source><year>2002</year><month>02</month><day>9</day><volume>359</volume><issue>9305</issue><fpage>515</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)07683-3</pub-id><pub-id pub-id-type="medline">11853818</pub-id></nlm-citation></ref><ref id="ref42"><label>42</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhide</surname><given-names>A</given-names> </name><name name-style="western"><surname>Shah</surname><given-names>PS</given-names> </name><name name-style="western"><surname>Acharya</surname><given-names>G</given-names> </name></person-group><article-title>A simplified guide to randomized controlled trials</article-title><source>Acta Obstet Gynecol Scand</source><year>2018</year><month>04</month><volume>97</volume><issue>4</issue><fpage>380</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1111/aogs.13309</pub-id><pub-id pub-id-type="medline">29377058</pub-id></nlm-citation></ref><ref id="ref43"><label>43</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>KF</given-names> </name></person-group><article-title>Randomized controlled trials</article-title><source>Clin Obstet Gynecol</source><year>1998</year><month>06</month><volume>41</volume><issue>2</issue><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1097/00003081-199806000-00005</pub-id><pub-id pub-id-type="medline">9646957</pub-id></nlm-citation></ref><ref id="ref44"><label>44</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>KF</given-names> </name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names> </name><name name-style="western"><surname>Moher</surname><given-names>D</given-names> </name></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title><source>J Pharmacol Pharmacother</source><year>2010</year><month>07</month><volume>1</volume><issue>2</issue><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.4103/0976-500X.72352</pub-id><pub-id pub-id-type="medline">21350618</pub-id></nlm-citation></ref><ref id="ref45"><label>45</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novick</surname><given-names>G</given-names> </name></person-group><article-title>Is there a bias against telephone interviews in qualitative research?</article-title><source>Res Nurs Health</source><year>2008</year><month>08</month><volume>31</volume><issue>4</issue><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1002/nur.20259</pub-id><pub-id pub-id-type="medline">18203128</pub-id></nlm-citation></ref></ref-list></back></article>